Cytogenetic and molecular characterization in gonadal tissue of patients with ovotesticular syndrome and gonadal dysgenesis 46,XY and 46,XX

María Carolina Manotas,1 Mary García-Acero,1 Daniel González,1 Camila Bernal,1 Mariana Guerra,1 Olga Moreno-Niño,1 Fernando Suárez,1,2 Camila Céspedes,1,2 Catalina Forero,1,2 Jaime Pérez,1,2 Adriana Rojas.1

Abstract

Objectives: The etiology of gonadal dysgenesis and the ovotesticular syndrome is unknown in most cases. The aim of the study was to perform cytogenetic and molecular characterization of a group of patients with ovotesticular syndrome and complete gonadal dysgenesis from peripheral blood and gonadal tissue samples.

Materials and methods: A total of 6 patients were included, 3 with 46,XX ovotesticular syndrome diagnosis, 1 diagnosed with 46,XY ovotesticular syndrome; 1 suspected with 46,XX gonadal dysgenesis, and 1 with 46,XY complete gonadal dysgenesis.

Results: All patients were evaluated with karyotype, fluorescence in situ hybridization (FISH) for SRY, multiplex ligation-dependent probe amplification (MLPA) and comparative genomic hybridization (aCGH) in peripheral blood samples. In cases with available gonadal tissue, the levels of genetic expression of SOX3, SRY, and SOX9 were determined by real-time PCR and immunofluorescence.

Rearrangements involving SRY gene were ruled out. No deletions/duplications or copy-number variations (CNVs) were identified as the etiology for the sexual development disorder in any of the studied patients. In one case of 46,XX ovotesticular syndrome, the gonadal karyotype was different from the karyotype in peripheral blood. Aberrant expression of SOX3 and SOX9 in gonadal tissue was observed in one case of 46,XX ovotesticular syndrome.

Conclusions: Lower levels of SRY and SOX9 expression were documented in the gonadal tissue of a case of 46,XY ovotesticular syndrome, in comparison with the levels in human cellular lines of embryonic testicle and Sertoli cells. Cytogenetic and molecular studies of gonads complementary to peripheral blood studies have the potential of enhancing the understanding of sexual development disorders in patients who are XX or XY in peripheral blood.

Key Words: gonadal dysgenesis, ovotesticular syndrome, FISH, MLPA, aCGH, SRY

Corresponding author:
* Adriana Rojas,
Dirección Instituto de Genética Humana,
Facultad de Medicina,
Email: rojas-adriana@javeriana.edu.co

Received: May 15, 2021
Accepted: August 05, 2021


1 Pontificia Universidad Javeriana, Bogotá, Colombia.
2 Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia.

https://doi.org/10.48193/rmu.v81i4.779
Introduction

Sexual development in mammals is genetically determined. It is defined at a phenotypical level by the development of gender-specific anatomy, physiology, and behavior. At a cellular level, sex is defined by the chromosomally complement and the genetic orchestration.\(^1,2\)

Sex-specific gonadal development starts with the formation of the bipotential gonad, which differentiates to testicular or ovarian tissue. The differentiation process depends on the activation of testis-specific or ovary-specific pathways, with parallel repression of the opposite pathway.\(^3,4\)

---

Resumen

**Objetivos:** La etiología de la disgenesia gonadal y el síndrome ovotesticular se desconoce en la mayoría de los casos. Para realizar la caracterización citogenética y molecular de un grupo de pacientes con síndrome ovotesticular y disgenesia gonadal completa a partir de muestras de sangre periférica y tejido gonadal.

**Material y métodos:** Se incluyeron un total de 6 pacientes, 3 con diagnóstico de síndrome ovotesticular 46, XX, uno diagnosticado con 46, XY síndrome ovotesticular; uno con sospecha de disgenesia gonadal 46, XX y otro con disgenesia gonadal completa 46, XY.

**Resultados:** Todos los pacientes fueron evaluados con cariotipo, hibridación in situ fluorescente (FISH) para SRY, amplificación de sonda dependiente de ligación múltiple (MLPA) e hibridación genómica comparativa (aCGH) en muestras de sangre periférica. En los casos con tejido gonadal disponible, los niveles de expresión genética de SOX3, SRY y SOX9 se determinaron mediante PCR en tiempo real e inmunofluorescencia. Se descartaron reordenamientos relacionados con el gen SRY. No se detectaron delecciones/duplicaciones o variaciones en el número de copias (NVC) como etiología del trastorno del desarrollo sexual en ninguno de los pacientes estudiados. En un caso de síndrome ovotesticular 46, XX, el cariotipo gonadal era diferente del cariotipo en sangre periférica. Se observó expresión aberrante de SOX3 y SOX9 en tejido gonadal de un caso con síndrome ovotesticular 46, XX.

**Conclusiones:** Se documentaron niveles más bajos de expresión de SRY y SOX9 en comparación con los niveles en líneas celulares humanas de testículo embrionario y Sertoli en el tejido gonadal de un caso con síndrome ovotesticular 46, XY. Los estudios citogenéticos y moleculares de las gónadas como complemento del estudio de sangre periférica tienen el potencial de enriquecer la comprensión de los trastornos del desarrollo sexual en pacientes que son XX o XY en sangre periférica.

**Palabras clave:**
Disgenesia gonadal, síndrome ovotesticular, FISH, MLPA, aCGH, SRY
The process for testis differentiation requires the participation of genes that belong to the SOX family. The SRY, located in the chromosome Y, was the first gene of the SOX family to be identified. This gene encodes a transcription factor which is sufficient and necessary to induce testis development. After its translation, the SRY protein translocates to the nucleus and interacts with the steroidogenic factor 1 (SF-1). The SRY protein and SF-1 bind to equal or similar places located within a testis-enhancer region in SOX9, inducing SOX9 expression. It has been determined that SF-1 (NR5A1 gene) regulates different developmental and functional aspects of the suprarenal gland and reproductive system. The activation of the expression of the AHM gene that encodes the Anti-Müllerian factor or hormone (AMH) is prominent among those aspects. The activation of the AMH is also regulated by the binding of the WT1 transcription factor to the Anti-Müllerian hormone receptor 2 (AMHR2) promoter. The WT1 has been described as a transcription factor necessary for early gonad development. The WT1 and LHX9 function together as direct activators of SF-1. Another gene involved in sexual development is NR0B1 (DAX1 protein). This gene, located in chromosome X (p21.3), encodes an orphan nuclear receptor that functions as a transcriptional repressor for many other genes, including NR5A1 and some genes that encode steroidogenic enzymes.

In ovarian differentiation, the participation of WNT4, RSPO1, and B-catenin (CTNNB1) is known. In XX gonads, the WNT4 and RSPO1 signaling factors favor and stabilize the expression of the transcription factor CTNNB1 (known as B-catenin), which participates in SOX9 genetic repression. The WNT4 is widely known as a necessary factor for early ovarian development.

Alterations in the testis-specific or ovarian-specific signaling pathways during gonadal development result in ‘disorders of sex development’ (DSD). DSD are defined as congenital conditions with atypical gonadal or anatomic development of chromosomal sex. Collectively, DSD occur in fewer than 1 in 4,500-5,000 live births. DSD include a clinical spectrum ranging from hypospadias (1 in 200-300 births) to more severe conditions (exact prevalence unknown). Such is the case of the 46,XY or 46,XX ovotesticular syndrome and 46,XY or 46,XX gonadal dysgenesis. The presence of internal and external female genitalia despite a 46,XY karyotype is the main characteristic of 46,XY complete gonadal dysgenesis, a DSD formerly known as XY sex reversal. Conversely, 46,XX gonadal dysgenesis is a primary ovarian failure that leads to premature ovarian insufficiency in otherwise normal 46,XX. The presence, histologically confirmed, of testicular and ovarian tissue in a case of 46,XX or 46,XY karyotype, defines the ovotesticular syndrome. The ovotesticular syndrome was previously known as true hermaphroditism. There is a hypothesis of an alteration in the signaling pathways involved in gonadal development as the cause for DSD, but the etiology of gonadal dysgenesis and ovotesticular syndrome in most cases is unknown.

Regarding XY gonadal dysgenesis, two types have been described: Complete (or pure), and partial. Partial gonadal dysgenesis is characterized by the presence of ambiguous genitalia, with or without Müllerian structures. Genes involved in partial gonadal dysgenesis include: SRY (by genic deletion or loss-of-function mutation); NR5A1 (by loss-of-function mutation).
mutations); DHH (by loss-of-function mutation, homocygous or heterocygous, affecting Leydig’s cell differentiation); and MAP3K1 (heterocygous gain-of-function mutations, associated with increased β-catenine expression and SOX9 suppression).\(^{(21–23)}\) Also, in patients with 46,XY gonadal dysgenesis, partial Xp duplications, including NR0B1 gene and 9p chromosomal deletions, including DMRT1 and DMRT2 genes, have been described.\(^{(21–24)}\) Molecular mechanisms involving DMRT1 and DMRT2 leading to gonadal dysgenesis are not completely understood.\(^{(24)}\)

Testicular syndrome, or 46,XX sex reversal, is caused by translocations involving SRY gene in 80% of the cases.\(^{(25)}\) Regarding SRY-negative cases, copy number variations (CNVs) affecting SOX3, SOX9, and NR5A1 genes, have been described.\(^{(25–28)}\) The SOX3 encodes a protein similar to SRY, sharing 90% of aminoacid identity in their DNA-binding HMG domain.\(^{(29)}\) Like SRY, this protein works synergistically with SF1 in the activation of the SOX9-enhancing region.\(^{(30)}\)

For the 46,XX ovotesticular syndrome, a small proportion of individuals with this condition have a fragment of the Y chromosome that includes the SRY gene, translocated to one of the X chromosomes. Likewise, CNVs involving SOX9, SOX3, and NR0B1;\(^{(18)}\) and a recurrent variant (p.Arg92Gln) in heterozygous status in NR5A1 have been described.\(^{(31)}\) However, 46,XY ovotesticular syndrome is extremely rare and represents approximately 10-12.5% of ovotesticular syndrome cases. Pathogenic variants involving SRY, SOX9, DMRT1, and NR0B1 genes have been described as the cause.\(^{(32)}\)

The objective of this paper was two-fold. First, to characterize the cytogenetic and molecular characterization of a group of patients with ovotesticular syndrome and complete gonadal dysgenesis from peripheral blood and gonadal tissue samples. Second, to analyze the role of pro-testis- and pro-ovarian-pathway genes in the clinical phenotype.

**Materials and Methods**

**Subjects of Research**

This study was approved by the Ethics Committee of the Hospital Universitario San Ignacio, Bogotá D.C., Colombia (FM-CIE-0445-17). The informed consent was obtained from the subjects of research: 4 patients with 46,XX SRY(-) DSD (3 cases with ovotesticular syndrome diagnosis and 1 case of suspected gonadal dysgenesis), and 2 patients with 46,XY SRY(+) DSD (1 case with ovotesticular syndrome and 1 case with gonadal dysgenesis) (Fig. 1). All individuals were evaluated by the transdisciplinary joint committee of the Hospital San Ignacio, Bogotá D.C., Colombia. Genetic tests included karyotype, FISH for SRY, and MLPA from blood samples.\(^{(38)}\) In some cases, the tests were also performed in gonadal tissue. In this study, all selected patients were analyzed for CNVs in DNA samples from peripheral blood. In cases where a biopsy was performed as part of the diagnostic approach, molecular tests were also performed from cultures of gonadal tissue fragments (Fig. 1).
Biological samples

Peripheral blood samples were used for karyotype, FISH, MLPA, and CGH. In some cases, gonad biopsies were obtained (cases 1, 4, and 6). Gene-expression experiments used samples of Sertoli cell cultures, isolated from human adult testicle (ScienCell#4520) as control tissue. In addition, cell line HS 1. Tes (ATCC CRL7002™) was used. This cell line is composed of human testis cells of second-trimester embryo.

Cytogenetic Analysis (Karyotype and FISH)

A cytogenetic analysis was performed from a lymphocyte culture obtained in peripheral blood and stimulated with phytohaemagglutinin (Gibco 10576015), following the protocol described by the research group. The gonad karyotype was obtained from gonadal tissue biopsy cultures. The tissue was mechanically digested and cultured with RPMI medium and 20% SFB. Chromosomes prepared in slides were treated with HCl and Wright stain for G-banding. A total of 50 cells in metaphase were analyzed with a 550-band resolution. Molecular cytogenetic analysis through fluorescence in situ hybridization (FISH) was performed with the use of an SRY-specific gene probe (SRY probe, Cytocell Aquarius). This reagent contains probes labelled in blue for the X chromosome centromere (DXZ1), a specific probe for SRY gene labelled in red (Yp11.31), and probes labelled in green fluorescence for Yq12 (DYZ1).
Extraction of genomic DNA

The extraction of DNA from peripheral blood and the gonad biopsy was performed using the Quick-DNA™ Universal kit, following the manufacturer’s instructions. The concentration and purity of the DNA were evaluated by spectrometry with the NanoDrop™. The quality of the DNA was assessed through electrophoresis in 1% agarose gel.

Multiplex ligation-dependent probe amplification (MLPA)

Possible deletions and duplications of SOX9, NR0B1, NR5A1, SRY, and WNT4 genes were studied with the MLPA SALSA P185-B2 Intersex kit (08 version; May 7, 2015) (MRC Holland), following the manufacturer’s instructions. After 35 PCR-amplification cycles, the amplification products were separated with the genetic analyzer ABI 3100. The data was analyzed using the Coffalyser (MRC Holland®). Each sample underwent duplicate analysis. Peak areas for each probe were normalized to the average of peak areas in the three controls. Samples of DNA that showed a reduction or an increase in the values of the MLPA peak area were analyzed again using the same procedure.

Matrix-comparative genomic hybridization (CGH)

The analysis of CNVs was performed with CGH using peripheral blood DNA and gonadal tissue culture, with a minimum DNA concentration of 66,592 ng/ul. The extracted DNA was sent to Macrogen Inc. for processing of the array chromosomal study with the Comparative Genomic Hybridization (Array-CGH) technique on an Illumina Infinium OmniExpress-24 platform. A bioinformatics analysis was performed with the GenomeStudio v2011.1 Genotyping 1.9.4, cnvPartition_v3.2.0. software. Genomic coordinates have been obtained from the reference human sequence NCBI37/hg19 (UCSC Genome Browser 2009).

Real time PCR (qPCR)

Messenger RNA levels for SRY, SOX9, and SOX3 genes were determined by q-PCR in gonadal tissue, Hs 1.Tes, and Sertoli cells. For all qPCR assays, RNA was isolated from tissue and/or cellular cultures with 100% confluence using the agent Trizol (Invitrogen®), following the manufacturer’s specifications. After RNA collection and quantification, the corresponding cDNA was synthetized. Once cDNA was procured, qPCR amplifications were performed using specific primers for SOX3, SOX9, and SRY (Table SI). For each 10 µl of q-PCR-TR reaction, 2.5 µl of DNA from the sample were added to a mixture containing 5 µl of SYBR Green (Invitrogen®), 0.5 µl of each primer in a 10 µM concentration, and 1.5 µl of ultrapure nuclease-free water. The results were analyzed using the Ct comparative method or 2-ΔΔCt as a strategy for relative quantification, with GAPDH as the reference gene. Gene expression results were graphically represented and analyzed with the software GraphPad Prim, version 6.
Immunofluorescence

Protein expression of SOX3, SOX9, and SRY was evaluated through indirect immunofluorescence in cultured cells from right and left gonads of a case with ovotesticular 46,XX SRY (-) DSD and in Sertoli cells as the positive control. On each slide, 100,000 cells from gonadal culture were seeded for immunofluorescence. Cells were fixed, washed, permeabilized, and incubated with primary antibodies directed against SRY (Anti-SRY antibody [OT13C8] ab140309) 1:100; SOX9 (Anti-SOX9 ab3697) 1:100; and SOX3 (Anti-H-SOX3 AF2569 R&D systems). The secondary antibodies were Alexa Fluor 594 Donkey Anti-Goat IgG (orange fluorochrome), Alexa Fluor 488 Invitrogen Goat Anti-Mouse IgG (green fluorochrome), and Alexa Fluor 647 Invitrogen Goat Anti-Rabbit IgG (red fluorochrome). Finally, slide mounting was performed with 7 ul of mounting medium ProLongTM Gold Antifade Mountant with DAPI (Invitrogen, P36931) for staining of contrast nuclei. Images with a 640 x 640 pixels resolution were obtained with a laser scan confocal microscope FV1000 (Olympus, Tokyo, Japan) using the oil immersion objective with UPLSAPO 60 x 1.35 NA. Images were processed using the software ImageJ.

Results

Six patients with DSD were included: 3 with 46,XX SRY(-) ovotesticular syndrome diagnosis, 1 patient with 46,XY SRY(+) ovotesticular syndrome diagnosis, 1 patient suspected with 46,XX SRY(-) gonadal dysgenesis, and 1 patient with complete 46,XY SRY(+) gonadal dysgenesis (Table I).
<table>
<thead>
<tr>
<th>DSD Type</th>
<th>Case</th>
<th>Assigned sex</th>
<th>External phenotype</th>
<th>Internal phenotype</th>
<th>Gonadal biopsy</th>
<th>Gonadal karyotype</th>
<th>Peripheral blood karyotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>46,XX SRY(-)</td>
<td>1</td>
<td>M</td>
<td>1.8 cm genital tubercle, distal penis urinary meatus, palpable gonads, and urogenital sinus</td>
<td>No deferent duct, but a fibrous remnant with origin at the deep inguinal ring, crossing the midline to merge with the contralateral, was found</td>
<td>RG: ovarian tissue with stroma and ovoctes</td>
<td>92,XXXX[8]/46,XX[42]</td>
<td>46,XX</td>
</tr>
<tr>
<td>Ovotesticular</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46,XY SRY(+)</td>
<td>2</td>
<td>M</td>
<td>Genitalia with hyperpigmented labioscrotal folds, without palpable gonads, 1 cm-long phallus, urinary meatus at the base of the phallus with mixed introitus</td>
<td>Uterus and gonads</td>
<td>RG: testis differentiation</td>
<td>Not available</td>
<td>46,XX</td>
</tr>
<tr>
<td>Ovotesticular</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suspected</td>
<td>3</td>
<td>M</td>
<td>3 cm genital tubercle, 1.3 cm-long urethral plate, hypospadiac meatus in perineal region, mild penoscrotal transposition</td>
<td>Spermatic cord, deferent duct, e p i d i d y m i s dissociated from the gonad</td>
<td>Incisional biopsy of gonad with reddish and velvety appearance shows seminiferous tubules, compatible with testicular tissue. Incisional biopsy of yellowish-brown gonad shows Graff follicles, compatible with ovarian tissue.</td>
<td>Not available</td>
<td>46,XX</td>
</tr>
<tr>
<td>46,XX SRY(-)</td>
<td>4</td>
<td>F</td>
<td>7.5 cm x 2.5 cm genital tubercle, labioscrotal folds, urethral orifice, vaginal introitus orifice, 1.5 cm perineal body</td>
<td>Rudimentary uterus. Right uterine tube ending in proximity with righ, 2.5 cm, and intra-abdominal gonad. More hypoplastic left uterine tube, ending in 0.5 cm irregular and soft gonad</td>
<td>RG: testicular tissue and ovarian stroma without follicles</td>
<td>46,XY SRY(+)</td>
<td>46,XY</td>
</tr>
<tr>
<td>gonadal dysgenesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46,XY SRY(+)</td>
<td>5</td>
<td>M</td>
<td>3 cm genital tubercle, Prader 4, bilateral palpable gonads</td>
<td>Uterus and intra-abdominal gonads</td>
<td>Right and left ovaries negative for malignancy. Left ovary with follicular cysts</td>
<td>Not available</td>
<td>46,XX</td>
</tr>
<tr>
<td>gonadal dysgenesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46,XX SRY(+)</td>
<td>6</td>
<td>F</td>
<td>External genitalia with hypotrophic labia majora and labia minora; normal clitoral hood and clitoris, 1.5 cm genital introitus</td>
<td>Right uterine tube. Gonads located directly above the internal inguinal ring. Epididymis, and a deferent duct</td>
<td>RG/LG: streak gonad. Müllerian remnants, uterine tube.</td>
<td>46,XY SRY(+)</td>
<td>46,XY</td>
</tr>
</tbody>
</table>
**Cases with ovotesticular syndrome 46,XX SRY(-) diagnosis**

**Case 1**

Case 1 was an individual with ambiguous genitalia, assigned male. Physical examination during neonatal period showed a 1.8 cm genital tubercle, distal penis urinary meatus, palpable gonads, and urogenital sinus. The patient had peripheral blood karyotype 46,XX; negative FISH for SRY (Fig. 2 A and B), negative MLPA Intersex, and negative aCGH for CNVs associated with ovotesticular syndrome. Karyotype in gonadal tissue showed a mosaicism characterized by 2 cell lines 92,XXXX[8]/46,XX[42]. The results of conventional cytogenetic, FISH and MLPA assays were included in a previous work of our research group.(33)

Figure 2. Cytogenetic analysis case 1. A. Karyotype by G-banding in peripheral blood, 46,XX. B. SRY FISH in peripheral blood

The image shows the metaphase of a 46,XX SRY (-) cell obtained with a Cytocell detection kit that uses three fluorescent probes. X chromosome centromere region (DXZ1) labelled blue, SRY gene (Yp11.31) labelled red, and Yq12 (DYZ1) labelled with green fluorescence. The results of conventional cytogenetic, FISH and MLPA assays were included in a previous work of our research group.

Levels of mRNA for SRY, SOX9, and SOX3 in gonadal tissue were determined by qPCR. Results from right and left gonads showed that expression levels of SRY and SOX9 mRNA were lower than the levels detected in Sertoli cells and embryonic human testis cells. Regarding SOX3, an increased expression was found in the left gonad (Fig. 3 A). Such expression levels of SRY and SOX9 in both gonads were consistent with low protein levels detected in immunofluorescence assays (Fig. 3 B). Regarding SOX3, protein expression was found only in the left gonad, which correlates with findings for mRNA (Fig. 3 B).
Figure 3. Gene expression of SOX3, SOX9, and SRY

A. Gene expression of SOX3, SOX9 and SRY mRNA relative to GAPDH in right and left gonads of the case with 46,XX SRY(−) ovotesticular syndrome (case 1). B. Immunofluorescence for SOX3, SOX9 and SRY in right and left gonads in case 1 and Sertoli cell as control. Alexa fluor 594 Donkey Anti-Goat IgG used as secondary antibody for SOX3 (orange fluorochrome), Alexa fluor 488 Invitrogen Goat Anti-Mouse IgG for SRY (green fluorochrome), Alexa fluor 647 Invitrogen Goat Anti-rabbit IGG for SOX9 (red fluorochrome). Nuclei are observed stained in blue.

Case 2

Case 2 was an individual with ambiguous genitalia, assigned male. The patient had karyotype with 46,XX chromosomic complement, SRY-negative FISH, and negative MLPA. No CNVs were detected with aCGH from peripheral blood DNA. There are no gonadal cytogenetic and/or molecular results for this patient, as no gonadal tissue was available for the study.

Case 3

Case 3 was an individual assigned male, with evidence of hypospadias and bilateral cryptorchidism. Laparoscopy showed gonads of mixed aspect. One gonad had a reddish and velvety appearance, and
the incisional biopsy showed seminiferous tubules, compatible with testicular tissue. The other gonad was yellowish-brown and the incisional biopsy showed Graff follicles, compatible with ovarian tissue. The patient had peripheral blood 46,XX karyotype, SRY-negative FISH, and negative MLPA Intersex. No pathogenic CNVs were detected with aCGH from peripheral blood DNA. There are no gonadal cytogenetic and/or molecular results for this patient, as no gonadal tissue was available for the study.

**Case diagnosed with 46,XY SRY(+) ovotesticular syndrome**

**Case 4**

Case 4 was an individual assigned female who underwent laparoscopy at age 12 due to primary amenorrhea. Histological examination of the left gonad biopsy showed uterine tube fragment, deferent duct fragment, and epididymal fragments. Histological examination in the right gonad showed evidence of testis with atrophic changes and an area suggestive of ovarian stroma. A new gonadal biopsy performed 3 years later showed gonadoblastoma in the right gonad. The patient had peripheral blood 46,XY, ish Yp11.31(SRY+) karyotype, negative MLPA Intersex, and negative aCGH for pathogenic CNVs. Gonadal karyotype, FISH, and MLPA results were consistent with those in peripheral blood. The aCGH from gonadal tissue did not detect CNVs associated with ovotesticular syndrome. Examination of genomic DNA from the right gonad showed a heterozygous loss of the arr[hg37]:2q14.2(121746975-121747688)x1 region involving the GLI2 gene.

For mRNA expression levels of SRY, SOX9, and SOX3, SRY levels were similar to levels in Sertoli cells and lower than levels in the Hs1. Tes in the right gonad. Relative SOX9 mRNA levels showed a differential expression in each gonad: The left gonad exhibited lower expression levels, while the right gonad showed nearly a five-fold increase compared to the control. The SOX3 mRNA expression showed an increase only in the left gonad (Fig. 4).

**Figure 4.** Gene expression of SOX3, SOX9, and SRY relative to GAPDH expression in right and left gonads in the 46,XY SRY(+) ovotesticular syndrome case (case 4).
Case suspected with 46,XX SRY(-) gonadal dysgenesis
Case 5

Case 5 was an individual assigned male. Biopsy of right and left gonads showed ovarian tissue, with follicular cysts in the left one. The patient had peripheral blood 46,XX karyotype, SRY-negative FISH, negative MLPA Intersex, negative SRY sequencing, and negative CNVs by aCGH from peripheral blood DNA. There are no gonadal cytogenetic and/or molecular results in this patient, as no gonadal tissue was available for the study.

Case with 46,XY SRY(+) gonadal dysgenesis
Case 6

Case 6 was an individual assigned female, in study for amenorrhea at age 12, without evidence of uterus in imaging studies. Diagnostic laparoscopy showed two gonads located directly above the internal inguinal ring, epididymis, and a deferent duct. No Müllerian remnants were found. Gonadal biopsy reported streak gonad, Müllerian remnants, and right uterine tube. The patient had peripheral blood 46,XY.ish Yp11.31(SRY+) karyotype, negative MLPA for NR0B1, NR5A1, SOX9, SRY, WNT4 deletion/duplication, and aCGH negative for CNVs associated with gonadal dysgenesis. Results of karyotype, FISH, MLPA, and aCGH in gonadal tissue were consistent with those in peripheral blood.

For SRY, SOX9 and SOX3 mRNA levels, the right gonad had SRY levels similar to those in Sertoli cells and lower than the ones in Hs1.Tes. Relative SOX9 mRNA levels were lower than levels in Sertoli cell and higher than levels in Hs1.Tes. The SOX3 expression was higher compared to Sertoli cells and Hs1.Tes.

In the left gonad, SRY levels were similar to those in Sertoli cells and lower than the ones in Hs1.Tes, while SOX9 levels were lower compared to Sertoli cells and Hs1.Tes. For SOX3, higher relative expression levels were observed compared to Sertoli cells, and similar levels to those observed in Hs1.Tes (Fig. 5).

Figure 5. Gene expression of SOX3, SOX9, and SRY relative to GAPDH in right and left gonads from the 46,XY SRY (+) gonadal dysgenesis case (Case 6).
Discussion

This paper presents 3 patients with 46,XX ovotesticular syndrome, 1 with 46,XY ovotesticular syndrome, 1 suspected with 46,XX gonadal dysgenesis, and 1 with 46,XY complete gonadal dysgenesis. Chromosomal rearrangements involving SRY gene were ruled out in the three patients during the initial diagnostic approach. Unexplainable cases of ovotesticular syndrome or gonadal dysgenesis can emerge from pathogenic variants in the pro-ovarian or pro-testis pathways. CNVs are detected in approximately 21.5% of DSD cases. For this reason, after ruling out deletions or duplications in the main genes (NR5A1, NR0B1, SOX9, SRY, and WNT4) of such pathways, a possible CNV involved in the patient’s phenotype was assessed through aCGH. No CNVs were detected, however, that could explain the DSD of at least one of the cases presented, which falls into the expectations due to the test diagnostic performance.

In cases with access to gonadal tissue, cytogenetic and molecular characteristics were analyzed through karyotype, aCGH, and genic expression levels for SRY, SOX9, and SOX3. The study of SOX3 was considered, given the synergistic function of SOX3 with SF1 in the activation of the SOX9 enhancer region and due to evidence of its etiological role for XX male (sex reversal) with genomic rearrangements involving the SOX3 regulatory region. In case 1, with 46,XX ovotesticular syndrome, SOX3 expression levels in gonads were higher than levels in Sertoli and Hs1.Tes. Such findings might relate to the mosaicism found in gonadic tissue, mos 92,XXXX[8]/46,XX[42], given that tetraploidy is associated with chromosomal unbalance in gene expression. This unbalance would explain the observed levels of SOX3 expression. The difference between karyotype in peripheral blood and karyotype in gonadal tissue is remarkable, however, given that chromosomal mosaicsisms or chimerism in gonads have been previously observed, even with the presence of cells containing Y chromosome only in gonads. The above-mentioned is supported by the hypothesis that in DSD which are unexplainable by studies in peripheral blood, gonadal mosaicism might explain the clinical phenotype of some patients, which justifies studies in gonadal biopsy.

In case 4 with 46,XY ovotesticular syndrome, gonadal SOX3 expression levels were higher, compared to normal human Sertoli cells and Hs1.Tes. Also, gonadal SRY and SOX9 expression levels were lower than levels in Hs1.Tes and Sertoli, respectively. A finding such as this, might explain the presence of ovarian stroma. Also, the study of CNVs for the right gonad showed a heterozygous deletion in 2q14.2 involving the GLI2 gene (glioma-associated oncogene 2 for the zinc finger protein), which encodes a transcription factor that participates in the Hedgehog signaling pathway. The Hedgehog pathway is involved in determining cellular destination and proliferation, and organ pattern during embryo development. The differentiation of fetal testis and postnatal and adult ovaries is especially important among such functions. Expression of GlI2, together with GlI1 has been observed in fetal Leydig cells. GlI2 and GlI1 might play redundant functions in the differentiation process. Physical and functional interaction of GLI1 and GLI2 has recently been described in humans as regulating the expression of target genes, such as BCL2, MYCN, PTCH2, IL7, and CCD1 in pancreatic tumor cells PANC1. It is still to be determined whether those genes play a similar
In case 5, suspected with 46,XX SRY(-) gonadal dysgenesis and assigned sex male, cytogenetic and molecular studies in peripheral blood did not elucidate the clinical condition’s origin. It is remarkable that the biopsy of gonadal tissue reports a right ovary and a left ovary with follicular cysts, especially as hormonal studies ruled out hyperandrogenism that might explain the virilization (data not shown). Evidently, there is not a confirmed diagnosis as of this date. Definition of 46,XX SRY (-) gonadal dysgenesis as a primary ovarian failure that leads to premature ovarian insufficiency in otherwise normal 46,XX females.(16) For these reasons, the study presents this as a possible case of gonadal dysgenesis with atypical presentation. Although the underlying cause is unknown in most cases, alterations have been identified in some of the involved genes, including homozygous or compound heterozygous inactivating mutations in the gene of the follicle-stimulating hormone receptor (FSHR), mutations in the BMP15 gene, and mutations in the NR5A1 gene. Inactivating FSHR mutations are inherited in a recessive autosomal pattern; BMP15 mutations are X-linked inherited; and NR5A1 are dominant autosomal, in most cases. (43,44) In another connection, the study of the expression of some genes in gonads of 46,XX SRY(-) patients with a masculine gonadal phenotype suggests that these types of conditions can be explained in some cases by alterations in gene expression. Kojima et al. in 2008, compared SOX9, NR0B1, Ad4BP / NR5A1, WT-1, GATA-4 and AMH expression in testis tissue of four 46,XX SRY (-) patients, with XY and XX normal controls. Their study found SOX9 expression levels in testis of these patients to be 1.9 times higher than levels in XY normal testis, while Ad4BP / NR5A1, NR0B1 y HAM expression levels were lower compared with the normal XY control.(45) Also, copy number alterations were studied for these genes, although changes were not found at that level. Such findings indicate that SOX9 overexpression is critical in sex determination in 46,XX SRY(-) males, that reduced expression of genes such as Ad4BP/ NR5A1, NR0B1, and HAM might also contribute to a masculine phenotype in these patients,(44) and that alterations in expression of genes involved in sexual differentiation are not necessarily related to CNVs. This suggests that it is biologically plausible that epigenetic regulatory mechanisms are related to sex determination and gonadogenesis.

In case 6, with 46,XY SRY(+) gonadal dysgenesis, SOX9 expression patterns are conspicuous. Results for SRY expression in both gonads were similar to the expression in Sertoli cells, however, SOX9 expression was very low compared to the control. Such low expression levels might explain a failure of the male differentiation process despite the presence of SRY. For the sexual determination of most mammals, Sry gene expression induces the embrionary bipotential gonad to a testis destination via pre-Sertoli cell differentiation. These cells are essential, in fact, for testis differentiation. The expression pattern for Sry is strictly time/space controlled, and it is limited to Sertoli cells precursors. In mice, approximately 4 hours after the start of Sry expression, SOX9 is upregulated in Sertoli cell precursors. Analyses in the bipotential gonad have shown that Sry or Sox9 expression suffices to induce male development.(45,46) For all these reasons,
the authors highlight the limitation of gene expression assessment with a precise time determination during the embryonic period. The authors consider their paper an approach to gathering knowledge about gene expression and its important role in gonad differentiation in patients with DSD.

Conversely, no direct relationship was found between the SOX3 gene and DSD in the cases of this study. The findings, however, lead to the conclusion that the SOX3 gene expresses in non-differentiated gonadal tissue. In some cases, it might be involved in the clinical phenotype of patients with DSD. This shows that SOX3 overexpression is, as previously discussed, fundamental for intervention in the sexual determination pathway.(30)

It is also important to emphasize that malignancy is associated with DSD, mainly with the 46,XY DSD.(47) There’s an estimated risk of gonadoblastoma of 15-35% for gonadal dysgenesis and 3% for ovotesticular syndrome. In this study, the patient in case 4 with 46,XY SRY(+) ovotesticular syndrome developed a gonadoblastoma, which was detected incidentally during a diagnostic laparoscopy that took a biopsy of the right gonad. Neoplastic transformation has been associated with deregulation of the tandem repetition region of TSPY, an acknowledged tumor-suppressor gene located inside the Y chromosome gonadoblastoma locus (GBY).(48,49) This gene plays normal roles in masculine germinial cells proliferation and differentiation, but it expresses ectopically in early and late stages of gonadoblastomas, in situ testicular carcinoma (the pre-malignant precursor for all testicular germinal-cell tumors), seminoma and non-seminoma. The aberrant expression of TSPY induces stimulation of protein synthesis, acceleration of cell proliferation, and tumorigenicity.(48)

It is worth noting that, currently, fewer than 20% of patients with DSD receive a precise genetic diagnosis. This justifies a continued exploration of new pathways and genes involved in the process of sex differentiation,(50) as it will allow further understanding of the underlying molecular mechanisms for human sexual development pathology, including, for instance, diagnostic cytogenetic and molecular studies in gonads as a complement to peripheral blood studies. Such studies would be a potential source for understanding the clinical conditions of patients with DSD that are XX or XY in peripheral blood.

Conclusion

This study shows that, in some cases, cytogenetic and molecular studies in peripheral blood are insufficient for diagnosing patients with DSD. A complementary approach, including gonadal cytogenetic and molecular analysis, can potentially improve diagnosis and enrich the understanding of DSD clinical manifestations that are XX or XY in peripheral blood.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This research protocol was approved by the Ethics Committee of the Hospital Universitario
San Ignacio (FM-CIE-0445-17) and the School of Medicine of the Pontificia Universidad Javeriana.

**Patient consent for publication**

The data and results presented in this study were anonymized and we obtained the patients' consent to publish them.

**Acknowledgements**

We would like to thank all the patients and families who participated in this study.

**Competing interests**

The authors declare that there are no competing interests.

**Funding**

This work was funded by HUSI 2017-171. M.G.A., and it also received the Young Researcher grant from COLCIENCIAS (grant 761/2016).

**CRediT Taxonomy**

M.C.M., M.G.A., D.G., C.B., M.G., O.M.N., and A.R. designed and performed the experiments and analyzed the data. M.C.M., F.S., C.C., J.P., and A.R provided technical and conceptual advice and analyzed the results. A.R. and O.M.N supervised the research and analyzed the data. M.C.M., D.G and A.R. wrote the main parts of the manuscript.

**References**


Cytogenetic and molecular characterization in gonadal tissue of patients with ovotesticular... Manotas M, C., et al.


